Getting on the critical path: better evaluation tools for drug discovery and development

Drug Discovery Today

Volumn 11, Issue 17-18, 2006, Pages 773-774

  Hrusovsky, Kevin ^a  

^a Caliper Life Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; SUNITINIB;

BIOINFORMATICS; BIOLUMINESCENCE; DRUG INDUSTRY; EDITORIAL; FOOD AND DRUG ADMINISTRATION; HUMAN; MEDICAL RESEARCH; MICROFLUIDICS; NONHUMAN; PRODUCTIVITY;

BIOLOGICAL MARKERS; DRUG DESIGN; TECHNOLOGY, PHARMACEUTICAL;

EID: 33747797979     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2006.07.014     Document Type: Editorial

References (2)

1. Mendel D.B., et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res. 9 (2003) 327-337
2. Tufts Center for the Study of Drug Development Impact Report (2006) New drugs entering clinical testing in top 10 firms jumped 52% in 2003-05. Analysis and Insight into Critical Drug Development Issues, 8, Tufts University